Vnitr Lek 2024, 70(1):E8-E14 | DOI: 10.36290/vnl.2024.013

The liver manifestation of metabolic syndrome is now called MASLD - an up-to-date view of the most common liver disease today

Václav Šmíd1, Karel Dvořák1, 2
1 IV. interní klinika - klinika gastroenterologie a hepatologie, Všeobecná fakultní nemocnice v Praze a 1. lékařská fakulta, Univerzita Karlova, Praha
2 Oddělení gastroenterologie a hepatologie, Krajská nemocnice Liberec, a. s.

Non-alcoholic fatty liver disease together with alcohol-related liver disease represent the most common chronic liver diseases in the Czech population. Both could - according to their severity - manifest as a whole spectrum of clinical pictures from simple steatosis to cirrhosis with its serious complications, especially portal hypertension and hepatocellular carcinoma. Due to increasing prevalence of diabetes mellitus type 2 and obesity, the first disease mentioned above gains importance and this article is discussig its diagnosis and treatment options. At the same time, the authors take the liberty of drawing the reader's attention to a significant change in the nomenclature of liver diseases placing much greater emphasis on the associated cardiometabolic risks. At the same time, the wishes of the patients were reflected and stigmatizing terms "non-alcoholic" and "fatty" were omitted. The name steatotic liver disease (SLD), which affects various etiologies of steatosis, was chosen as an umbrella term. The original NAFLD is now called MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), i.e. liver steatosis associated with metabolic dysfunction. MASLD includes patients who have hepatic steatosis, one of the five cardiometabolic risk factors and drink minimal amounts of alcohol. The term steatohepatitis is still considered an important pathophysiological concept and has therefore been retained. The preferred name is now MASH - Metabolic-Associated SteatoHepatitis.

Keywords: liver cirrhosis, liver fibrosis, liver steatosis, MASLD, metabolic syndrome, steatohepatitis.

Accepted: February 23, 2024; Published: February 26, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šmíd V, Dvořák K. The liver manifestation of metabolic syndrome is now called MASLD - an up-to-date view of the most common liver disease today. Vnitr Lek. 2024;70(1):E8-14. doi: 10.36290/vnl.2024.013.
Download citation

References

  1. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851-861. DOI: 10.1016/S2468-1253(22)00165-0. Go to original source... Go to PubMed...
  2. Le MH, Yeo YH, Zou B, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022;28:841-850. DOI: 10.3350/cmh.2022.0239. Go to original source... Go to PubMed...
  3. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023;101133. DOI: 10.1016/j.aohep.2023.101133. Go to original source... Go to PubMed...
  4. WHO European Regional Obesity Report 2022. ISBN 978-92-890-5773-8. 2022.
  5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. DOI: 10.1002/hep.28431. Go to original source... Go to PubMed...
  6. Dvorak K, Hainer R, Petrtyl J, et al. The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159:442-8. DOI: 10.5507/bp.2014.033. Go to original source... Go to PubMed...
  7. Yip TC, Vilar-Gomez E, Petta S, et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology. 2023;77:1404-1427. DOI: 10.1002/hep.32774. Go to original source... Go to PubMed...
  8. Mantovani A, Petracca G, Csermely A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2022. DOI: 10.1136/gutjnl-2022-327672. Go to original source... Go to PubMed...
  9. Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23:521-530. DOI: 10.1016/S1470-2045(22)00078-X. Go to original source... Go to PubMed...
  10. Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology. 2023;77:323-338. DOI: 10.1002/hep.32542. Go to original source... Go to PubMed...
  11. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487-493. DOI: 10.2337/dci19-0066. Go to original source... Go to PubMed...
  12. Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:903-913. DOI: 10.1016/S2468-1253(21)00308-3. Go to original source... Go to PubMed...
  13. Halámková V. Healthy lifestyle parameters assessment in patients with type 2 diabetes mellitus and fatty liver. 2023, 83 s. Bakalářská práce (Bc.), Univerzita Karlova v Praze, 1. lékařská fakulta 2023.
  14. Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29:e8-e12. DOI: 10.1097/MEG.0000000000000776. Go to original source... Go to PubMed...
  15. Memel ZN, Wang J, Corey KE. Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence? Clin Liver Dis (Hoboken). 2022;19:101-105. DOI: 10.1002/cld.1172. Go to original source... Go to PubMed...
  16. Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67:829-846. DOI: 10.1016/j.jhep.2017.05.016. Go to original source... Go to PubMed...
  17. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85. DOI: 10.1056/NEJMoa0907929. Go to original source... Go to PubMed...
  18. Kuchay MS, Misra A. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. Diabetes Metab Syndr. 2022;16:102446. DOI: 10.1016/j.dsx.2022.102446. Go to original source... Go to PubMed...
  19. Akuta N, Kawamura Y, Fujiyama S, et al. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. Intern Med. 2020;59:1931-1937. DOI: 10.2169/internalmedicine.4398-19. Go to original source... Go to PubMed...
  20. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384:1113-1124. DOI: 10.1056/NEJMoa2028395. Go to original source... Go to PubMed...
  21. Drenth JPH, Schattenberg JM. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert Opin Investig Drugs. 2020;29:1365-1375. DOI: 10.1080/13543784.2020.1839888. Go to original source... Go to PubMed...
  22. Brunt EM, Clouston AD, Goodman Z, et al. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol. 2022;76:1030-1041. DOI: 10.1016/j.jhep.2022.01.011. Go to original source... Go to PubMed...
  23. Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2023;8:179-191. DOI: 10.1016/S2468-1253(22)00338-7. Go to original source... Go to PubMed...
  24. Bruha R, Dvorak K, Fejfar T, Smid V, Trunecka P. Doporučený postup České hepatologické společnosti ČLS JEP pro diagnostiku a léčbu Nealkoholové tukové choroby jater (NAFLD). Gastroent Hepatol. 2020;74(2):103-110. DOI: 10.14735/amgh2020103. Go to original source...
  25. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402. DOI: 10.1016/j.jhep.2015.11.004. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.